Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
1 Year : From Dec 2018 to Dec 2019
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that clinical data and important findings from studies of lead candidate odevixibat (A4250) in biliary atresia, Alagille syndrome and progressive familial intrahepatic cholestasis have been selected for presentation at the 52nd European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting, being held June 5-8, 2019, at the Scottish Event Campus in Glasgow, Scotland.
Details of the presentations are as follows:
Title: Effects of the ileal bile acid transport inhibitor A4250 on serum bile acids, pruritus and sleep in patients with Alagille syndrome: phase 2 study results Presentation Number: H-O-006 Session: Plenary Session: Hepatology Date / Time: Friday, June 7, 8:40-8:50 a.m. BST / 3:40-3:50 a.m. EST Presenter: Dr. Ulrich Baumann, Professor of Pediatric Gastroenterology and Hepatology, Hannover Medical School; Hannover, Germany
Title: Development of patient- and observer-reported outcome measures for paediatric cholestatic liver diseases Poster Number: H-P-138Session: Poster ExhibitionDate / Time: Friday, June 7, 2-2:45 p.m. BST / 9-9:45 a.m. EST Presenter: Dr. Richard J. Thompson, Professor of Molecular Hepatology, Institute of Liver Studies, King’s College Hospital; London, United Kingdom
Title: Effects of the ileal bile acid transport inhibitor A4250 on pruritus and serum bile acids in patients with biliary atresia: phase 2 study results Poster Number: H-P-029Session: Poster Exhibition Date / Time: Friday, June 7, 2-2:45 p.m. BST / 9-9:45 a.m. EST Presenter: Dr. Ulrich Baumann, Professor of Pediatric Gastroenterology and Hepatology, Hannover Medical School; Hannover, Germany
Title: Impact of an ileal bile acid transporter inhibitor versus partial external biliary diverson in progressive familial intrahepatic cholestasis – a case providing direct comparison of medical and surgical therapiesPoster Number: H-P-130Session: Poster Exhibition Date / Time: Friday, June 7, 2-2:45 p.m. BST / 9-9:45 a.m. EST Presenter: Christoph Slavetinsky, MD, Ph.D., Pediatric Gastroenterology and Hepatology, University Children's Hospital Tubingen; Tubingen, Germany
The ESPGHAN Annual Meeting brings together more than 4,600 participants from 100 countries to exchange new ideas and discuss the latest research in gastroenterology, hepatology and nutrition. For more information about the conference, visit https://www.espghancongress.org.
About Albireo Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, odevixibat (A4250), is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis (PFIC). Albireo’s clinical pipeline also includes two Phase 2 product candidates. Albireo’s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world.
Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Investor Contact: Hans Vitzthum, LifeSci Advisors, LLC, 212-915-2568Media Contact: Heather Anderson, 6 Degrees, 980-938-0260, email@example.com
Source: Albireo Pharma, Inc.